NCT05864014View on ClinicalTrials.gov

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

March 3, 2025

Study Completion Date

September 30, 2025

Conditions
Chemotherapy-Induced Thrombocytopenia
Interventions
DRUG

Hetrombopag

Hetrombopag

DRUG

Hetrombopag plus Placebo

Hetrombopag plus Placebo

DRUG

Placebo

Placebo

Trial Locations (1)

150000

Hematology Tumor Research Center of Harbin First Hospital, Haerbin

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY